He is also a member of the Princess Margaret Tumor Immunotherapy Program and is the Clinical Head of the Immune Monitoring Team at the Princess Margaret, where his group performs a wide variety of immunologic assays to examine the impact of therapies on immune phenotype and function. Dr. Butler’s research focus is on the development of novel therapies and clinical trials that include targeted therapy, immune modulation and adoptive T-cell therapy.